Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis

Soman, Midhun; Huang, Li-Cong; Cai, Wen-hui; Xu, Jun-Bi; Chen, Junyao; He, Ran; Ruan, H; Xu, Xiangrong; Qian, Zhida; Zhu, Xiaoming

doi:10.1097/gme.0000000000001161

Cited by 37 publications

(18 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of its impact on well-being, loss of fertility, selfesteem, body image, sense of femininity, and other aspects of health, POI may adversely affect a woman's relationship with her partner, the quality of intimacy, and even a woman's motivation to start a new relationship 98 . Aside from reproductive function and psychosocial aspects contributing to sexual dysfunction, women with POI may experience reduced androgen production in addition to the loss of estrogen 99,100 . Because androgens are believed to play an important role in sexual functioning in women, and trials of testosterone treatment in women have shown improvements in sexual function 101 , loss of androgens may have a negative impact on sexual functioning.…”

Section: Sexual Healthmentioning

confidence: 99%

Premature ovarian insufficiency: a toolkit for the primary care physician

et al. 2021

View full text Add to dashboard Cite

Premature ovarian insufficiency (POI) refers to the loss of ovarian activity before the age of 40 years, which leads to hypoestrogenism and amenorrhea. The diagnosis of POI in a young woman has potentially life-changing physical and emotional consequences for both the patient and her family. Therefore, it is very important that the diagnosis is correct and that it is made in a timely manner. Unfortunately, the diagnosis and therefore the effective treatment of POI are often delayed, which underlines the need for education of the broad medical community on the issue. A panel of menopause experts reviewed and critically appraised the literature, and present: (1) the diagnostic approach to POI, (2) the investigation of the etiology of this condition, (3) the therapeutic strategy regarding both hormone replacement therapy and fertility, and (4) the long-term follow-up and management for ensuring quality of life, as well as urogenital, cardiovascular, bone and mental health. The ultimate goal of this article is to provide a complete toolkit for the primary care physician to have easy access to all the information needed for the optimal management of women with POI, in the context of evidence-based and personalized medicine. HIGHLIGHTS Premature ovarian insufficiency occurs in 1% of the female population of reproductive age, yet the diagnosis is often delayed, with severe physical and emotional consequences for the patient. Primary care physicians should be aware of the possibility of premature ovarian insufficiency in young women presenting with menstrual irregularity. Prompt initiation of hormone replacement therapy ensures quality of life and prevents osteoporosis and cardiovascular disease. Women seeking fertility should be referred to specialists to discuss assisted reproduction options.

show abstract

Section: Sexual Healthmentioning

confidence: 99%

Premature ovarian insufficiency: a toolkit for the primary care physician

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Despite controversial results in the literature, many women with POI may present low serum testosterone levels when compared to non-POI women of the same age. (24,25,(27)(28)(29)(30)(31) Although this testosterone deficiency seems to contribute to the manifestation of POI, there is not enough evidence to recommend routine testosterone administration or replacement therapy in these patients. (22,32) Premature ovarian insufficiency: A hormonal treatment approach Testosterone can be currently prescribed for women with POI diagnosed with hypoactive sexual desire disorder with no contraindication.…”

Section: How To Monitor and Follow Up Women With Poi?mentioning

confidence: 99%

Premature ovarian insufficiency: A hormonal treatment approach

Benetti‐Pinto

Júnior

Maciel

et al. 2020

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

“…Diminished ovarian reserve (DOR) is a common cause of otherwise unexplained infertility, as well as, early ovarian hor-monal insufficiency and related endocrinopathies. Recently published meta-analysis that included 14 studies shows that individuals with premature ovarian insufficiency (POI) have lower concentration levels of androgens in comparison with healthy controls: DHEAS, testosterone and androstendione [40]. Others estimated that suboptimal DHEAS concentrations are quite common and were found in 65% of women with diminished ovarian reserve DOR [41].…”

Section: Supplementation Of Dhea For Fertility Improvementmentioning

confidence: 99%

Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women — position statement of expert panel of Polish Menopause and Andropause Society

et al. 2020

View full text Add to dashboard Cite

Dehydroepiandrosterone (DHEA) concentration decreases with age, therefore, DHEA has been considered a hormone that reduces the symptoms associated with aging, so the usefulness of DHEA in premenopausal and postmenopausal women, and the options of hormone therapy have received a large amount of attention. The effectiveness of DHEA in the premenopausal women remains unclear, while in postmenopausal women with coexisting estrogens deficiency is controversial. Despite many years of study, the use of DHEA is still controversial, especially regarding its effectiveness. The aim of present article was to evaluate DHEA specific effects on metabolic parameters, bone mineral density, insulin resistance as well as the therapeutic potential of DHEA in pre-and postmenopausal women using measures of sexual activity, cognition and well-being. The summary of this article is the position statement of expert group of the Polish Menopause and Andropause Society regarding the efficacy and safety of DHEA supplementation in women. We concluded, that currently available clinical trials and meta-analyses indicate that DHEA supplementation is effective in women with adrenal insufficiency and chronically treated with exogenous glucocorticoids, postmenopausal women with low bone mineral density and/or osteoporosis, premenopausal women with sexual disorders and low libido, and in women with vulvovaginal atrophy due to menopause or genitourinary syndrome of menopause. Currently available clinical trials also suggest that DHEA supplementation is probably effective in postmenopausal women with hypoactive sexual disorders, infertile women with diminished ovarian reserve, women suffering from depression and anxiety, and women with obesity and insulin resistance. No serious adverse effects have been reported.

show abstract

Serum androgen profiles in women with premature ovarian insufficiency: a systematic review and meta-analysis

Cited by 37 publications

References 50 publications

Premature ovarian insufficiency: a toolkit for the primary care physician

Premature ovarian insufficiency: a toolkit for the primary care physician

Premature ovarian insufficiency: A hormonal treatment approach

Supplementation of dehydroepiandrosterone (DHEA) in pre- and postmenopausal women — position statement of expert panel of Polish Menopause and Andropause Society

Contact Info

Product

Resources

About